107 related articles for article (PubMed ID: 9452344)
1. Pretreatment and posttreatment positron emission tomographic scan imaging in a 20-year-old patient with Wilson's disease.
Cordato DJ; Fulham MJ; Yiannikas C
Mov Disord; 1998 Jan; 13(1):162-6. PubMed ID: 9452344
[TBL] [Abstract][Full Text] [Related]
2. Relationship between striatal glucose consumption and copper excretion in patients with Wilson's disease treated with D-penicillamine.
Hefter H; Kuwert T; Herzog H; Arendt G; Stremmel W; Feinendegen LE
J Neurol; 1993 Nov; 241(1):49-53. PubMed ID: 8138822
[TBL] [Abstract][Full Text] [Related]
3. Effect of penicillamine and zinc on iron metabolism in Wilson's disease.
Medici V; Di Leo V; Lamboglia F; Bowlus CL; Tseng SC; D'Incà R; Irato P; Burra P; Martines D; Sturniolo GC
Scand J Gastroenterol; 2007 Dec; 42(12):1495-500. PubMed ID: 17994470
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
[TBL] [Abstract][Full Text] [Related]
5. Effect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.
De Volder A; Sindic CJ; Goffinet AM
J Neurol Neurosurg Psychiatry; 1988 Jul; 51(7):947-9. PubMed ID: 3264567
[TBL] [Abstract][Full Text] [Related]
6. Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease.
Schlaug G; Hefter H; Nebeling B; Engelbrecht V; Weiss P; Stöcklin G; Seitz RJ
J Neurol; 1994 Oct; 241(10):577-84. PubMed ID: 7836960
[TBL] [Abstract][Full Text] [Related]
7. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers.
Westermark K; Tedroff J; Thuomas KA; Hartvig P; Långström B; Andersson Y; Hörnfeldt K; Aquilonius SM
Mov Disord; 1995 Sep; 10(5):596-603. PubMed ID: 8552111
[TBL] [Abstract][Full Text] [Related]
8. Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson's disease.
Kuwert T; Hefter H; Scholz D; Milz M; Weiss P; Arendt G; Herzog H; Loken M; Hennerici M; Feinendegen LE
Eur J Nucl Med; 1992; 19(2):96-101. PubMed ID: 1563446
[TBL] [Abstract][Full Text] [Related]
9. [Pathogenesis and treatment of Wilson's disease].
Nagy J; Vincze Z; Folhoffer A; Horváth A; Csák T; Zelkó R
Acta Pharm Hung; 2003; 73(4):237-41. PubMed ID: 15279036
[TBL] [Abstract][Full Text] [Related]
10. Clinical considerations for an effective medical therapy in Wilson's disease.
Weiss KH; Stremmel W
Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease.
Schumacher G; Platz KP; Mueller AR; Neuhaus R; Steinmüller T; Bechstein WO; Becker M; Luck W; Schuelke M; Neuhaus P
Clin Transplant; 1997 Jun; 11(3):217-24. PubMed ID: 9193846
[TBL] [Abstract][Full Text] [Related]
12. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
[TBL] [Abstract][Full Text] [Related]
13. Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson's disease patients.
Sturniolo GC; Mestriner C; Irato P; Albergoni V; Longo G; D'Incà R
Am J Gastroenterol; 1999 Feb; 94(2):334-8. PubMed ID: 10022625
[TBL] [Abstract][Full Text] [Related]
14. Iron accumulation in the liver of male patients with Wilson's disease.
Shiono Y; Wakusawa S; Hayashi H; Takikawa T; Yano M; Okada T; Mabuchi H; Kono S; Miyajima H
Am J Gastroenterol; 2001 Nov; 96(11):3147-51. PubMed ID: 11721763
[TBL] [Abstract][Full Text] [Related]
15. Computed tomography in Wilson's disease.
Selekler K; Kansu T; Zileli T
Arch Neurol; 1981 Nov; 38(11):727-8. PubMed ID: 7305706
[TBL] [Abstract][Full Text] [Related]
16. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease.
Lozano Herrero J; Muñoz Bertrán E; Ortega González I; Gómez Espín R; López Espín MI
Gastroenterol Hepatol; 2012 Dec; 35(10):704-7. PubMed ID: 22609346
[TBL] [Abstract][Full Text] [Related]
17. Brief observations on the management of Wilson's disease.
Walshe JM
Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):1-3. PubMed ID: 122651
[No Abstract] [Full Text] [Related]
18. Brain iron accumulation in Wilson's disease: A longitudinal imaging case study during anticopper treatment using 7.0T MRI and transcranial sonography.
Dusek P; Skoloudik D; Maskova J; Huelnhagen T; Bruha R; Zahorakova D; Niendorf T; Ruzicka E; Schneider SA; Wuerfel J
J Magn Reson Imaging; 2018 Jan; 47(1):282-285. PubMed ID: 28376267
[TBL] [Abstract][Full Text] [Related]
19. Epileptic status immediately after initiation of D-penicillamine therapy in a patient with Wilson's disease.
Berger B; Mader I; Damjanovic K; Niesen WD; Stich O
Clin Neurol Neurosurg; 2014 Dec; 127():122-4. PubMed ID: 25459257
[No Abstract] [Full Text] [Related]
20. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
